IL6 and colitis: Importantly, isoliquiritigenin mainly distributes in gastrointestinal tract and has potential to ameliorate the dextran sulfate sodium-induced colitis through inhibiting MAPK pathway (13) and inhibit colitis-associated tumorigenesis through hampering M2 macrophage polarization mediated by the interplay between prostaglandin E2 (PGE2) and interleukin-6 (IL-6) (14).